MetaCap

Who Owns Lineage Cell Therapeutics Stock?

NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.7719-0.0481 (-5.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
48.30%
Institutional holders
183
  • Institutions 48.3%
  • Insiders 4.9%
  • Public and other 46.8%

Who owns Lineage Cell Therapeutics stock?

Institutional investors own about 48.3% of Lineage Cell Therapeutics's shares, spread across 183 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 4.86% of LCTX.

The largest institutional holders are Broadwood Capital, Inc. (19.59%), Blackrock Inc. (5.48%) and Vanguard Capital Management LLC (3.47%). Together, the top 10 institutions control 40.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their LCTX positions and 2 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of LCTX

Lineage Cell Therapeutics top institutional holders
InstitutionShares% HeldChange
Broadwood Capital, Inc.49.56M19.59%0.0%
Blackrock Inc.13.87M5.48%+5.2%
Vanguard Capital Management LLC8.78M3.47%-3.1%
Defender Capital, LLC6.65M2.63%+0.8%
Geode Capital Management, LLC5.34M2.11%+0.8%
Raffles Associates Lp5.20M2.05%0.0%
Fifth Third Bancorp4.90M1.94%+6.5%
Millennium Management Llc3.02M1.19%-45.7%
State Street Corporation2.93M1.16%+26.4%
Vanguard Fiduciary Trust Co1.72M0.68%+2.8%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of LCTX

Lineage Cell Therapeutics top fund holders
FundShares% Held
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund5.91M2.34%
iShares Trust-iShares Russell 2000 ETF4.51M1.78%
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund2.96M1.17%
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.99M0.79%
iShares Trust-iShares Russell 2000 Growth ETF1.75M0.69%
iShares Trust-iShares Biotechnology ETF1.46M0.58%
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund1.20M0.48%
VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund1.05M0.42%
iShares Trust-iShares Micro-Cap ETF581.34K0.23%
SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund447.53K0.18%

Frequently asked questions

Who is the largest shareholder of Lineage Cell Therapeutics?

Broadwood Capital, Inc. is the largest institutional shareholder of LCTX, owning 19.59% of shares outstanding (49.56M shares) as of its latest 13F filing.

What percentage of Lineage Cell Therapeutics is owned by institutions?

Institutions own about 48.3% of LCTX shares and 50.8% of the public float.

How much of Lineage Cell Therapeutics do insiders own?

Insiders, such as officers and directors, own about 4.86% of LCTX shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related